@article{d4b86ff2e08e4b5e9bb383aaa04cd610,
title = "A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment",
keywords = "Attention deficit/hyperactivity disorder, Dopamine, Methylphenidate, Sustained attention",
author = "{Del Campo}, Natalia and Fryer, {Tim D.} and Hong, {Young T.} and Rob Smith and Laurent Brichard and Julio Acosta-Cabronero and Chamberlain, {Samuel R.} and Roger Tait and David Izquierdo and Ralf Regenthal and Jonathan Dowson and John Suckling and Baron, {Jean Claude} and Aigbirhio, {Franklin I.} and Robbins, {Trevor W.} and Sahakian, {Barbara J.} and Ulrich M{\"u}ller",
note = "Funding Information: This work was funded by a Pathfinder Award of the UK Medical Research Council [MRC, G0401099] and the Behavioural and Clinical Neuroscience Institute [BCNI], jointly funded by MRC and Wellcome Trust [MRC Ref G001354 and WT Ref 076244/ Z/04/Z]. N.D.C. was funded by the Gates Cambridge Trust when the work here presented was completed and is now employed by Cambridge Cognition. S.R.C. consults for Cambridge Cognition, P1Vital, and Shire Pharmaceuticals. T.W.R. is a consultant for Cambridge Cognition, Pfizer, Eli Lilly, GlaxoSmithKline, Allon Therapeutics, and Lundbeck, and receives royalties from Cambridge Cognition and Springer-Verlag. B.J.S. consults for Cambridge Cognition and holds shares in CeNeS. She has consulted for Novartis, Shire, GlaxoSmithKline, Eli Lilly and Boehringer-Ingelheim. She also receives an honorarium from the Journal of Psychological Medicine. U.M. has received research and educational grant support from Janssen-Cilag and honoraria or travel expenses from Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Pharmacia-Upjohn, and UCB Pharma.",
year = "2013",
month = nov,
doi = "10.1093/brain/awt263",
language = "English",
volume = "136",
pages = "3252--3270",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "11",
}